Tag: Nivolumab
Brentuximab vedotin + Immunotherapy Shows 98% ORR and 93% CR in...
Updated efficacy and safety results from Part C of a phase 2 single-arm trial (SGN35-027; ClinicalTrials.gov identifier: NCT03646123; EudraCT 2020-004027-17) evaluating brentuximab vedotin (Adcetris®; Seagen/Takeda)* in combination with the PD-1 inhibitor nivolumab (Opdivo®; Bristol-Myers Squibb) and standard chemotherapy agents doxorubicin (Adriamycin®) and dacarbazine (DTIC-Dome®/Imidazole) for the frontline treatment of patients with early-stage classical Hodgkin lymphoma (cHL).
Compared to Brentuximab Vedotin, Nivolumab Reduces Risk of Disease Progression in...
Compared to Brentuximab Vedotin, Nivolumab Reduces Risk of Disease Progression in Untreated Hodgkin Lymphoma
Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing...
Positive top-line data from a recently completed dose-escalation study of BDC-1001 in HER2-expressing solid tumors support the drug to advance into two Phase 2...
Novel pH Mechanism may Enhance On-Target Effects with Reduced Off-Tumor Toxicity
The development of antibody-based immunotherapies has, compared with conventional therapeutic strategies patients, transformed the therapeutic landscape in melanoma, non-small cell lung cancer, bladder cancer,...
ASH 2020: ECHELON-1 and ECHELON-2 and other Results with Brentuximab Vedotin
Presentations discussing brentuximab vedotin (Adcetris®; Seagen/Takeda) presented during the 62nd American Society of Hematology (ASH) Annual, Meeting, and Exposition, held virtually from December 5...
Brentuximab Vedotin in Combination with Chemotherapy Approved for Adults with Previously...
The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda) in combination with chemotherapy in adult patients with previously untreated...
AbbVie and Bristol-Myers Squibb Evaluate Telisotuzumab Vedotin and Nivolumab in c-Met...
A new clinical trial collaboration between AbbVie and Bristol-Myers Squibb Company will evaluate the combination of AbbVie's investigational antibody-drug conjugate telisotuzumab vedotin also known...
Nivolumab and DS-8201 to be Evaluated in HER2-Expressing Breast and Bladder...
Bristol-Myers Squibb and Daiichi Sankyo have agreed to collaborate in a clinical trial to evaluate the combination of Bristol-Myers Squibb’s immunotherapy nivolumab (Opdivo®) and...
Combination of Brentuximab Vedotin and Nivolumab Shows 85% Objective Response Rate...
An updated interim analysis from the ongoing phase I/II clinical trial evaluating brentuximab vedotin (Adcetris®; Seattle Gentics) and nivolumab (Opdivo®; Bristol-Myers Squibb) in relapsed...
Collaboration to Evaluate Combination of Nivolumab + Brentuximab Vedotin in Pivotal...
Bristol-Myers Squibb and Seattle Genetics have expanded their collaboration to evaluate the combination of the immunotherapy Nivolumab (Opdivo®) and the antibody-drug conjugate or ADC...
